e-Therapeutics – Phase I approval for clinical trials of cancer drug ETS2101. Buy, with a 91p target price. e-Therapeutics, the AIM-listed biotechnology company with a proprietary platform in network pharmacology – an innovative new approach to drug discovery based on the science of complex systems – is on track to report the first data from […]